CME Supported Symposium

FREE REGISTRATION - 2 FREE CME

Live Interactive Online

*Included with 4th HiD Registration 

​

View Program Brochure

AGENDA

Supported by an Educational Grant from AstraZeneca

Receive 2 AMA PRA Category 1 Credits

​

SATURDAY, AUGUST 22, 2020

3:35pm - 5:15pm

​

For more information, please contact us: info@tmioa.com  ●  (818) 342-1889

Program Description

Heart failure (HF) shares many pathophysiologic pathways with obesity, type 2 diabetes (T2D) and chronic kidney disease (CKD),
including hypertension, dyslipidemia, inflammation, oxidative stress, and increased renin-angiotensin-aldosterone system activity.
HF currently affects approximately 6.5 million individuals in the United States, but its prevalence is increasing. It is believed that
nearly 9% of the population worldwide above age 60 have HF, while in people with diabetes it may reach up to 24%. Heart failure
with preserved ejection fraction (HFpEF) is becoming almost as prevalent, soon to be more, as heart failure with reduced ejection
fraction (HFrEF). Patients with obesity, metabolic syndrome and diabetes, especially those who also have CKD, are particularly
susceptible to HF. In this CME satellite symposium we will exam the epidemiology, current CVOT relevant to HF and optimal
approaches to the prevention and management of HF.

Learning Objectives
Upon completion of this meeting, participants should be able to:
• Describe the etiology and pathophysiology of HF and its link to obesity, T2D, and CKD
• Recognize the differences between HF with reduced vs preserved ejection fraction
• Compare and contrast HF and renal risk reductions observed in outcomes trials with SGLT2 inhibitors involving patients
with and without type 2 diabetes
• Describe best practices in the prevention, diagnosis, and management of HFrEF and HFpEF in patients with and without type
2 diabetes
• Design optimal therapeutic regimens for the prevention and management patients with HF or at risk for HF

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, diabetologists, internists, family physicians, nurse
practitioners, physician assistants, and other healthcare professionals interested in the pathophysiology, prevention, and
management of heart failure in relation to associated conditions such as obesity, diabetes, cardiovascular and kidney disease.

FACULTY

Javed Butler, MD, MPH, MBA Chair

Patrick H. Lehan Chair in

Cardiovascular Research
Professor and Chairman,

Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City

School of Medicine
Kansas City, Missouri

Yehuda Handelsman, MD, MD, FACP, FNLA, FASPC, MACE Chair
Chair & Program Director
4th Heart in Diabetes
Medical Director & Principal Investigator,
The Metabolic Institute of America
Tarzana, California

Christian W. Mende, MD, FACP, FACN,
FASN, FASH, FAHA

Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Biykem Bozkurt, MD, PhD, FHFSA, FACC,
FAHA, FESC, FACP

President, Heart Failure Society of America
The Mary and Gordon Cain Chair,
W.A. “Tex” and Deborah Moncrief, Jr., Chair,
Professor of Medicine,
Medical Care Line Executive,

DeBakey VA Medical Center,
Director, Winters Center for

Heart Failure Research,
Associate Director,

Cardiovascular Research Institute,
Vice-Chair of Medicine,

Baylor College of Medicine
Houston, Texas

Muthiah Vaduganathan, MD, MPH

Cardiologist,
Brigham and Women’s Hospital
Instructor of Medicine,
Harvard Medical School
Boston, Massachusetts